COVID‐19 in solid organ transplant recipients
Open Access
- 15 July 2020
- journal article
- letter
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (1) , e13419
Abstract
First identified in December 2019, the novel severe acute respiratory syndrome coronavirus‐2 has spread widely. Coronavirus disease 2019 (COVID‐19) was declared a pandemic in March 2020. Post‐transplant patients appear to be particularly vulnerable. University of Arkansas for Medical Sciences (UAMS) is the only abdominal transplant institution in the state of Arkansas. Between March 25 to April 20, four transplant recipients with functioning grafts tested positive for COVID‐19. Three were African American; one was Hispanic. Median age was 62.5 years (range 49‐65). Three patients had received kidney transplant (KT). One had received a simultaneous liver‐kidney (SLK).Keywords
This publication has 19 references indexed in Scilit:
- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?International Journal of Antimicrobial Agents, 2020
- Covid-19 — Navigating the UnchartedNew England Journal of Medicine, 2020
- Coronaviruses and Immunosuppressed Patients: The Facts During the Third EpidemicLiver Transplantation, 2020
- COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progressionJournal of Antimicrobial Chemotherapy, 2020
- Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19Journal of Medical Virology, 2020
- Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppressionAmerican Journal of Transplantation, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosineDrug Discoveries & Therapeutics, 2019